{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T13:06:21Z","timestamp":1776431181235,"version":"3.51.2"},"reference-count":58,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Introduction: Non-muscle-invasive bladder cancer (NMIBC) represents approximately 78% of newly diagnosed bladder cancers and is characterized by high recurrence rates and variable progression risk. While transurethral resection of bladder tumor (TURBT) followed by intravesical therapy remains standard management, optimal treatment of high-risk and Bacillus Calmette-Guerin (BCG)-unresponsive disease remains controversial. Radiotherapy (RT), particularly in combination with chemotherapy, has been explored as a bladder-preserving alternative. Material and Methods: We conducted a narrative review of published literature evaluating the role of definitive RT in high-risk NMIBC, with emphasis on T1 disease. Retrospective series, prospective trials, meta-analyses, and contemporary guideline recommendations were examined. For each included study, we extracted data on the extent of TURBT (maximal vs. incomplete\/non-specified), use and type of concurrent chemotherapy, radiotherapy technique (3D-conformal, IMRT, or proton), treatment volume (bladder only vs. whole pelvis), and dose\/fractionation schedule. Results: Early studies evaluating RT alone demonstrated modest complete response rates. More recent approaches incorporating maximal TURBT followed by concurrent chemoradiotherapy report improved outcomes, with complete response rates of approximately 80\u201388% and 5-year overall survival comparable to surgical series. The phase II NRG\/RTOG 0926 trial in recurrent high-risk T1 disease after intravesical therapy failure demonstrated an 81% complete response rate and favorable bladder preservation outcomes. Meta-analytic data suggest 5-year recurrence-free survival around 54% and overall survival near 70%, although evidence remains limited and largely non-randomized. Advances in image-guided and hypofractionated RT may further improve therapeutic outcomes while limiting toxicity. Conclusions: while definitive chemoradiotherapy is a promising option for selected patients, it remains investigational and should be considered only in those who are unfit for or decline radical cystectomy. Prospective randomized studies are needed to better define its role in contemporary management.<\/jats:p>","DOI":"10.3390\/curroncol33040225","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:53:46Z","timestamp":1776426826000},"page":"225","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions"],"prefix":"10.3390","volume":"33","author":[{"given":"Lucas","family":"Resende Salgado","sequence":"first","affiliation":[{"name":"Department of Urology and Radiology, Mount Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Zaytoun","sequence":"additional","affiliation":[{"name":"Department of Urology and Radiology, Mount Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4176-8246","authenticated-orcid":false,"given":"Ahmed","family":"Rabie","sequence":"additional","affiliation":[{"name":"Department of Urology, Northwell Health, New York, NY 11042, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9265-994X","authenticated-orcid":false,"given":"Nicholas","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Urology and Radiology, Mount Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-1415","authenticated-orcid":false,"given":"Anthony","family":"Nehlsen","sequence":"additional","affiliation":[{"name":"Department of Urology and Radiology, Mount Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4100-473X","authenticated-orcid":false,"given":"Kristin","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Department of Urology and Radiology, Mount Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Dovey","sequence":"additional","affiliation":[{"name":"Department of Urology and Radiology, Mount Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anum","family":"Aamir","sequence":"additional","affiliation":[{"name":"Department of Urology and Radiology, Mount Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9376-8307","authenticated-orcid":false,"given":"Kunal K.","family":"Sindhu","sequence":"additional","affiliation":[{"name":"Department of Urology and Radiology, Mount Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","first-page":"10732748231152322","article-title":"Impact of Age at Diagnosis of Bladder Cancer on Survival: A Surveillance, Epidemiology, and End Results-Based Study 2004\u20132015","volume":"30","author":"Lin","year":"2023","journal-title":"Cancer Control. J. Moffitt Cancer Cent."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/bco2.323","article-title":"The potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care","volume":"5","author":"Sindhu","year":"2024","journal-title":"BJUI Compass"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","article-title":"Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018","volume":"74","author":"Cumberbatch","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1128\/CMR.12.1.97","article-title":"Relationship between Schistosomiasis and Bladder Cancer","volume":"12","author":"Mostafa","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Alouini, S. (2024). Risk Factors Associated with Urothelial Bladder Cancer. Int. J. Environ. Res. Public Health, 21.","DOI":"10.3390\/ijerph21070954"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Santos, L.L., Santos, J., Gouveia, M.J., Bernardo, C., Lopes, C., Rinaldi, G., Brindley, P.J., and da Costa, J.M.C. (2021). Urogenital Schistosomiasis\u2014History, Pathogenesis, and Bladder Cancer. J. Clin. Med., 10.","DOI":"10.3390\/jcm10020205"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA\/ASCO\/SUO Guideline (2017; Amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non\u2013muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: An individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline: 2024 Amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3810\/pgm.2011.05.2283","article-title":"Diagnosis and Management of Urothelial Carcinoma of the Bladder","volume":"123","author":"Tanaka","year":"2011","journal-title":"Postgrad. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(09)60491-8","article-title":"Bladder cancer","volume":"374","author":"Kaufman","year":"2009","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"key":"ref_18","first-page":"507","article-title":"Bladder Cancer: Diagnosis and Treatment","volume":"96","author":"DeGeorge","year":"2017","journal-title":"Am. Fam. Physician"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"23292","DOI":"10.1038\/s41598-025-04363-z","article-title":"Clinical relevance of the somatic mutational landscaping in predicting outcome of bladder cancer patients","volume":"15","author":"Nedjadi","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","article-title":"The health economics of bladder cancer: An updated review of the published literature","volume":"32","author":"Yeung","year":"2014","journal-title":"PharmacoEconomics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/bco2.316","article-title":"Combining theranostic\/particle therapy with immunotherapy for the treatment of GU malignancies","volume":"5","author":"Skalina","year":"2023","journal-title":"BJUI Compass"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.juro.2014.03.098","article-title":"Impact of Bladder Cancer on Health Related Quality of Life in 1,476 Older Americans: A Cross-Sectional Study","volume":"192","author":"Fung","year":"2014","journal-title":"J. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","article-title":"Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa\u2013pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non\u2013Muscle-Invasive Bladder Cancer on Tumor Recurrence","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Campistol, M., Lozano, F., Carrion, A., Ravent\u00f3s, C.X., Morote, J., and Trilla, E. (2025). Active Surveillance in Non-Muscle Invasive Bladder Cancer: A Systematic Review. Cancers, 17.","DOI":"10.3390\/cancers17101714"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.23.02510","article-title":"Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology\/RTOG","volume":"42","author":"Dahl","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_27","first-page":"451.e1","article-title":"Mitomycin C vs. Bacillus Calmette\u2013Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients\u2014A comparative analysis from a single center","volume":"42","author":"Scilipoti","year":"2024","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.043","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Sylvester","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/JU.0000000000004472","article-title":"Gemcitabine vs Bacillus Calmette-Gu\u00e9rin for Intravesical Therapy in Treatment-Na\u00efve Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer","volume":"213","author":"Khene","year":"2025","journal-title":"J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e223050","DOI":"10.1001\/jamanetworkopen.2022.3050","article-title":"Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non\u2013Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013","volume":"5","author":"Bree","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder Cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/bju.16371","article-title":"Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer","volume":"134","author":"Laukhtina","year":"2024","journal-title":"BJU Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.21.01003","article-title":"Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.21.01485","article-title":"Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial","volume":"40","author":"Funt","year":"2022","journal-title":"Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1464-410X.1986.tb09015.x","article-title":"Treatment of superficial (T1) tumours of the bladder by radical radiotherapy","volume":"58","author":"Quilty","year":"1986","journal-title":"Br. J. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0936-6555(05)80838-6","article-title":"Bladder cancer: Long-term follow-up results of patients treated with radical radiation","volume":"3","author":"Gospodarowicz","year":"1991","journal-title":"Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1200\/JCO.2006.05.8149","article-title":"Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: An alternative to intravesical therapy or early cystectomy?","volume":"24","author":"Weiss","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00066-008-1855-x","article-title":"Treatment options for high-risk T1 bladder cancer: Status quo and future perspectives of radiochemotherapy","volume":"184","author":"Weiss","year":"2008","journal-title":"Strahlenther. Und Onkol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.juro.2007.05.024","article-title":"A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder","volume":"178","author":"Harland","year":"2007","journal-title":"J. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_45","first-page":"786.e1","article-title":"Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer","volume":"39","author":"Pessoa","year":"2021","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Jocham","year":"2003","journal-title":"J. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","article-title":"Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: Results from an international cohort","volume":"57","author":"Fritsche","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.ijrobp.2025.06.1061","article-title":"Bladder Only vs. Whole Pelvis Radiotherapy in Trimodality Treatment for Lymph Node Negative Urothelial Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis","volume":"123","author":"Granda","year":"2025","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"TPS880","DOI":"10.1200\/JCO.2026.44.7_suppl.TPS880","article-title":"A phase III randomised control clinical trial of radiotherapy with radiosensitisation versus intravesical bacillus Calmette-Guerin therapy for high-risk non-muscle invasive bladder cancer: TRAIN","volume":"44","author":"Choudhury","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_52","unstructured":"(2020, January 01). NCT06770582. Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial. 3 June 2025. Available online: https:\/\/www.clinicaltrialsfinder.org\/trials\/nct06770582-testing-the-addition-of-the-immunotherapy-drug-pembrolizumab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.ijrobp.2005.10.023","article-title":"Proton beam therapy for invasive bladder cancer: A prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy","volume":"64","author":"Hata","year":"2006","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"i49","DOI":"10.1093\/jrr\/rrad027","article-title":"Proton beam therapy for muscle-invasive bladder cancer: A systematic review and analysis with Proton-Net, a multicenter prospective patient registry database","volume":"64","author":"Araya","year":"2023","journal-title":"J. Radiat. Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Ahangar, M., Mahjoubi, F., and Mowla, S.J. (2024). Bladder cancer biomarkers: Current approaches and future directions. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1453278"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1002301","DOI":"10.37349\/etat.2025.1002301","article-title":"Bladder cancer biomarkers","volume":"6","author":"Godlewski","year":"2025","journal-title":"Explor. Target. Anti-tumor Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5489\/cuaj.8386","article-title":"Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation","volume":"18","author":"Riveros","year":"2023","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_58","unstructured":"(2026, February 23). BRACE Trial: NCT06990061, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06990061."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/4\/225\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:30:34Z","timestamp":1776429034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/4\/225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":58,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["curroncol33040225"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33040225","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]}}}